These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 3019969

  • 1. Phase I/II trials of WR-2721 and cis-platinum.
    Glover D, Glick JH, Weiler C, Fox K, Turrisi A, Kligerman MM.
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1509-12. PubMed ID: 3019969
    [Abstract] [Full Text] [Related]

  • 2. Phase I trials of WR-2721 and cis-platinum.
    Glover D, Glick JH, Weiler C, Yuhas J, Kligerman MM.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1781-4. PubMed ID: 6090371
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
    Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM.
    J Clin Oncol; 1986 Apr; 4(4):584-8. PubMed ID: 3007686
    [Abstract] [Full Text] [Related]

  • 5. Phase I controlled trials of WR-2721 and cyclophosphamide.
    Glick JH, Glover D, Weiler C, Norfleet L, Yuhas J, Kligerman MM.
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1777-80. PubMed ID: 6090370
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is there cumulative or delayed toxicity from cis-platinum?
    Chiuten D, Vogl S, Kaplan B, Camacho F.
    Cancer; 1983 Jul 15; 52(2):211-4. PubMed ID: 6683119
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL.
    Semin Oncol; 1999 Apr 15; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
    Green D, Bensely D, Schein P.
    Cancer Res; 1994 Feb 01; 54(3):738-41. PubMed ID: 8306335
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies.
    Coia L, Krigel R, Hanks G, Comis R, Algazy K, Peters R, McCulloch W, Schien P.
    Int J Radiat Oncol Biol Phys; 1992 Feb 01; 22(4):791-4. PubMed ID: 1312076
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity.
    Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI.
    Cancer; 1991 Mar 15; 67(6):1518-24. PubMed ID: 1848154
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.